Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2024 06:56 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 06:05 ET
|
Fennec Pharmaceuticals Inc.
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has...
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
August 06, 2024 16:31 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
August 05, 2024 06:26 ET
|
Fennec Pharmaceuticals Inc.
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment...
Fennec Pharmaceuticals Announces Management Change
July 01, 2024 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian...
Fennec Announces Results of Annual Meeting
June 25, 2024 16:35 ET
|
Fennec Pharmaceuticals Inc.
Annual meeting voting results.
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 06:03 ET
|
Fennec Pharmaceuticals Inc.
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement...
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
May 07, 2024 18:15 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
March 21, 2024 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to...
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
March 19, 2024 06:01 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...